Carbapenem-resistant Enterobacteriaceae (CRE) – A Growing Superbug Population

Cara Wilder, Ph.D. Technical Writer, ATCC May 5, 2016





About ATCC

- Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas, VA
- World's premiere biological materials resource and standards development organization
- ATCC collaborates with and supports the scientific community with industry-standard biological products and innovative solutions
- Strong team of 400+ employees; over one third with advanced degrees



Established partner to global researchers and scientists





Outline



- 1. Background on antibiotic resistance
- 2. Emergence and spread of carbapenemresistant Enterobacteriaceae (CRE)
- 3. CRE strains available from ATCC
 - KPC
 - NDM
 - OXA-48



Multidrug Resistance (MDR) is an Emerging Threat

- Antimicrobial resistance is present in all parts of the world
- The CDC estimates that every year in the United States:
 - 2 million people become infected with antibiotic-resistant bacteria
 - **23,000** people die as a direct result of these infections
 - \$20 billion in excess direct healthcare costs
 - **\$35 billion** cost associated with lost productivity



Photo credit: NIAID



Bad Bugs, No Drugs: No ESKAPE!



Staphylococcus aureus Photo credit: F. DeLeo, NIAID <u>Enterococcus faecium</u>
<u>Staphylococcus aureus</u>
<u>Klebsiella sp.</u>
<u>Acinetobacter baumannii</u>
<u>Pseudomonas aeruginosa</u>
<u>Enterobacter sp.</u>
Gram -

These pathogens cause the majority of US hospital infections and can effectively "escape" the effects of antimicrobial therapeutics



Boucher HW, et al. Bad bugs, no drugs: no ESKAPE! An update from the IDSA. Clin Infect Dis 48(1): 1-12, 2009.

Multidrug Resistance is Widespread

Minimum Estimates of Morbidity and Mortality from Antibiotic-Resistant Infections

Antibiotic-Resistant Microorganism	Estimated Annual Number of Cases	Estimated Annual Number of Deaths
Carbapenem-resistant Enterobacteriaceae (CRE)	9,300	610
Extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL)	26,000	1,700
Vancomycin-resistant Enterococcus (VRE)	20,000	1,300
Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	80,000	11,000
Multidrug-resistant <i>Acinetobacter</i> (≥3 drug classes)	7,300	500
Multidrug-resistant <i>Pseudomonas</i> <i>aeruginosa</i> (≥3 drug classes)	6,700	440



National Action Plan for Combating Antibiotic-Resistant Bacteria

The White House – March 2015

Goals:

- Slow the emergence of resistant bacteria and prevent the spread of resistant infections
- Strengthen national One Health surveillance efforts to combat resistance
- Advance development and use of rapid and innovative diagnostic tests for identification and characterization of resistant bacteria
- Accelerate basic and applied research and development for new antibiotics, other therapeutics, and vaccines
- Improve international collaboration and capacities for antibiotic-resistance prevention, surveillance, control, and antibiotic research and development



The White House. National Action Plan for Combating Antibiotic-Resistant Bacteria, March 2015.

- Inherent resistance
- Genetic mutation
- Horizontal gene transfer
 - Transformation
 - Transduction
 - Conjugation





- Reduced drug accumulation
- Antibiotic alteration
- Metabolic bypass
- Modification of target sites
- Antibiotic degradation











Simply using antibiotics creates resistance. These drugs should only be used to treat infections.



CRE – Hazard Level Urgent

These are high-consequence antibiotic-resistant threats because of significant risks identified across several criteria. These threats may not be currently widespread but have the potential to become so and require urgent public health attention to identify infections and to limit transmission.



Carbapenem Resistance

- Carbapenem antibiotics
 - β-lactam antibiotic
 - Inhibit peptidoglycan synthesis

- Mechanisms of carbapenem-resistance
 - β-lactamase production combined with porin mutations
 - Carbapenemase production





CRE Definitions and Recommendations

CDC has defined CRE as Enterobacteriaceae that are:

- Resistant to any carbapenem antimicrobial (i.e. MIC of ≥4 µg/mL for doripenem, meropenem, or imipenem OR ≥2 µg/mL for ertapenem)
- Documented to produce carbapenemase



Escherichia coli

Photo credit: David Gregory & Debbie Marshall



CRE Definitions and Recommendations

- Lower CLSI break points allow easier detection
- More information is available:
 - CLSI M100-S25 2015
 - CDC 2015 CRE Toolkit
 - AHRQ Carbapenem-Resistant *Enterobacteriaceae* (CRE) Control and Prevention Toolkit

Agent	Previous Breakpoints (M100-S19) MIC (μg/mL)		Current Breakpoints (M100-S25) MIC (μg/mL)			
0	Susceptible	Intermediate	Resistant	Susceptible	Intermediate	Resistant
Doripenem				≤ 1	2	≥ 4
Ertapenem	≤ 2	4	≥ 8	≤ 0.5	1	≥ 2
Imipenem	≤ 4	8	≥ 16	≤ 1	2	≥ 4
Meropenem	≤ 4	8	≥16	≤ 1	2	≥ 4



CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Information Supplement (M100-S25), 2015.

Concerns About CRE as an Emerging Threat



Klebsiella pneumoniae Photo credit: NIAID

- Multidrug-resistant
- High mortality rates for invasive infections
 - Up to 50% in some studies
- Rapid spread in healthcare settings
- Potential to become widespread in the community
- Carbapenemase genes can be transmitted from one Enterobacteriaceae to another
- Increase in CRE strains
 - 1.2% in 2001 to 4.2% in 2011



CRE strains

Carbapenemase	Ambler Class	Known Bacterial Carriers
КРС	А	K. pneumoniae, E. coli, and Enterobacter spp.
NDM	В	E. coli, K. pneumoniae, and E. cloacae
VIM	В	P. aeruginosa and P. putida
IMP	В	Pseudomonas and Acinetobacter spp.
CMY	С	E. aerogenes
OXA	D	K. pneumoniae, E. coli, Acinetobacter spp.





Carbapenemase	Ambler Class	Known Bacterial Carriers
КРС	А	K. pneumoniae, E. coli, and Enterobacter spp.
NDM	В	E. coli, K. pneumoniae, and E. cloacae
VIM	В	P. aeruginosa and P. putida
IMP	В	Pseudomonas and Acinetobacter spp.
CMY	С	E. aerogenes
OXA	D	K. pneumoniae, E. coli, Acinetobacter spp.





Starter Marchannessen, Santaria Marchanne

Last-Ditch Resistance: More Countries, More Dire Results



An E. coli bacterium. PHOTOGRAPH BY THE PUBLIC HEALTHIMAGE LIBRARY, CDC GOV.

The frantic international hunt triggered by the discovery of genetically mobile resistance to colistin, a last-resort antibiotic, is producing many more findings this evening. The resistance factor is showing up in more countries, but, much

'Phantom Menace' Superbug Has Alarming Ability

Antibiotic resistance travels between bacteria





By Rob Quinn, Newser Staff Posted Dec 4, 2015 5:50 AM CST

This illustration released by the CDC depicts a group of carbapenem-resistant Enterobacteriaceae bacteria. (AP Photo/Centers for Disease Control)

(NEWSER) - The latest strains of antibioticresistant bacteria to give researchers sleepless nights aren't the most common-or even the most antibiotic-resistant-but they have an ability that could make them a serious danger to public health. They contain enzymes known as "OXA-48-like carbapenemases" that can break down antibiotics and transfer that ability to normal bacteria in the body through mobile pieces of DNA, reports the Washington Post. and Live Science. The enzymes have been nicknamed the "phantom menace" by researchers because they can be tough to detect. In a report issued this week, the CDC says it identified 43 cases in the US involving the superbug between June 2010 and August of this year, mainly involving people who had



Klebsiella pneumoniae Carbapenemase (KPC)

- KPC hydrolyzes all β-lactam agents
- Encoded by the plasmid-associated gene bla_{KPC}
- May be difficult to detect using higher (older) breakpoints
- The CDC has confirmed the presence of KPC throughout most of the United States





K. Pneumoniae Photo credit: David Dorward, Ph.D., NIAID



New Delhi Metallo-β-lactamase (NDM)

- Encoded by the plasmid-associated gene bla_{NDM}
- First identified in 2008
- It has since been detected worldwide





Enterobacteriaceae Photo credit: CDC



CDC. Healthcare-associated Infections (HAIs). Tracking CRE, 2015.

Oxacillinase-48 (OXA-48)

- Penicillinases that can hydrolyze penicillins and imipenem
- Encoded by the plasmid-associated gene bla_{OXA-48}
- First isolated in 2001 in Istanbul, Turkey, has since spread in Europe, the Middle East, India, North Africa, and the US





Acinetobacter sp. Photo credit: CDC



CRE – Identification

Modified Hodge Test Photo credit: James



- CHROM agar
- MacConkey agar plates supplemented with meropenem
- Modified Hodge Test
- Carba NP
- Antibiotic susceptibility disc testing
- PCR
- Check-Direct CPE assay (Check-Points)
- Next-generation sequencing



CRE – **Prevention**



Improve sanitation procedures and barrier precautions

- Hand hygiene
- Contact precautions
- Disposable equipment
- Environmental cleaning
- Chlorhexidine bathing
- Limit indwelling devices



CRE – **Prevention**

Implement a surveillance program and communicate outbreaks

- CRE screening of patients that meet prespecified criteria
- Screen contacts of CRE patients
- Laboratory notification
- Inter-facility communication/identification of CRE patients at admission





CRE – **Prevention**



Antimicrobial stewardship

- Promote the appropriate use of antimicrobials
- Appoint a drug expert
- Monitor and report antibiotic prescriptions and resistance patterns
- Educate clinicians about resistance and optimal prescribing



ATCC – Aiding the Scientific Community



ATCC provides top-quality, authenticated reference strains and associated molecular materials

- Enhance diagnostics
- Analyze novel therapeutics
- Improve sterility protocols



ATCC KPC Strains

ATCC [®] No.	Species	Strain Designation	Presence of Select
	Klobsielle en europening		him to the
BAA-1702	Kiebsiella pheumoniae	ART 2008133 [D-05, 1338]	DIG _{KPC} +/DIG _{NDM} -
BAA-1898™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-1899™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-1900™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-1902™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-1903™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-1904™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-1905™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-2078™	Klebsiella pneumoniae	-	bla _{KPC} +
BAA-2082™	Enterobacter hormaechei	-	bla _{KPC} +
BAA-2340™	Escherichia coli	1101362	bla _{KPC} +/bla _{NDM} -
BAA-2341™	Enterobacter cloacae	1101152	bla _{KPC} +/bla _{NDM} -
BAA-2342™	Klebsiella pneumoniae	1101160	bla _{KPC} +/bla _{NDM} -
BAA-2343™	Klebsiella pneumoniae	1101172	bla _{KPC} +/bla _{NDM} -
BAA-2344™	Klebsiella pneumoniae	1101200	bla _{KPC} +/bla _{NDM} -

KPC Strains Panel (ATCC[®] MP-24[™])



ATCC NDM Strains

ATCC [®] No.	Species	Strain Designation	Presence of Select Virulence Genes
BAA-2146™	Klebsiella pneumoniae	1000527, 7561	bla _{NDM} +/bla _{KPC} -
BAA-2452™	Escherichia coli	NDM-1	bla _{NDM} +/bla _{KPC} -
BAA-2468™	Enterobacter cloacae	1000654	bla _{NDM} +/bla _{KPC} -
BAA-2469™	Escherichia coli	1001728	bla _{NDM} +/bla _{KPC} -
BAA-2470™	Klebsiella pneumoniae subsp. pneumoniae	1002565	bla _{NDM} +/bla _{KPC} -
BAA-2471™	Escherichia coli	1100101	bla _{NDM} +/bla _{KPC} -
BAA-2472™	Klebsiella pneumoniae subsp. pneumoniae	1100975	bla _{NDM} +/bla _{KPC} -
BAA-2473™	Klebsiella pnemoniae	1100770	bla _{NDM} +/bla _{KPC} -
BAA-2566™	Escherichia coli		bla _{NDM} +/bla _{KPC} -
BAA-2578™	Klebsiella pneumoniae		bla _{NDM} +/bla _{KPC} -

NDM-1 Strains Panel (ATCC[®] MP-18[™])



ATCC OXA-48 Strains

ATCC [®] No.	Species	Strain Designation	Relevant Phenotype*
BAA-2523™	Escherichia coli	bMx# 1109131	Produces OXA-48
BAA-2524 [™]	Klebsiella pneumoniae subsp. pneumoniae	bMx# 1103199	Produces OXA-48
BAA-2525™	Providencia rettgeri	bMX# 1103204	Produces OXA-48

*Depositor statement

Antibiotic*	BAA-2523™	BAA-2524™	BAA-2525™
Meropenem	R	R	S
Ertapenem	R	R	I.
Imipenem	R	R	R

R = Resistant, S = Susceptible, I = Intermediate susceptibility

*Antibiotic susceptibility determined using E-Test Strips; results may vary depending on the assay and susceptibility cut-offs used



Microbial Strain Authentication



ATCC utilizes both classical and modern techniques

- Phenotypic analysis
- Genotypic analysis
- Functional analysis

No single method of identification is sufficient



Phenotypic Testing



Genotypic & Protein Testing





Verification of Drug Resistance

Modified Hodge Test



Recommended by CLSI and the CDC for the detection of carbapenemase production

Endpoint PCR



Endpoint PCR used to detect the presence or absence of genes required for antibiotic production

Antibiotic Profiling



- VITEK[®] 2 used to analyze resistance to various antibiotic classes
 - Penicillins
 - Cephalosporins
 - Carbapenems
 - Quinolones
 - Aminoglycosides



Enhance Your Research with ATCC Strains



ATCC – Leading the fight against superbugs!

- Rapid detection methods
- Innovative therapeutic techniques
- Novel antibiotics
- Updated sterility protocols



Conclusion

- Multidrug-resistant strains are an emerging problem throughout the world
- ATCC acquires, authenticates, and distributes clinically relevant strains that are essential to the scientific community
 - Phenotypic, genotypic, and functional testing
- KPC, NDM, and OXA strains are now available at ATCC
 - Individual strains
 - Microbial panels

Identity Purity Authenticity Homogeneity Stability Functionality



Enterobacteriaceae Photo credit: CDC



Thank you for joining today!

Register for more ATCC "*Excellence in Research*" webinars, or watch recorded webinars, at <u>www.atcc.org/webinars</u>.



Please email additional questions to: tech@atcc.org

